Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. is dated August 5, 2024, covering the month of August 2024. The report serves as a notice to shareholders regarding updates to the Proxy Statement for an Extraordinary Meeting of Shareholders scheduled for August 12, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is an update to the Proxy Statement previously furnished on July 8, 2024. The filing incorporates these changes by reference into the company's Registration Statements on Form S-8 and Form F-3.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors. The document focuses solely on the administrative update regarding the shareholder meeting notice.
Key Facts for Investors
- Scinai Immunotherapeutics Ltd. is holding an Extraordinary Meeting of Shareholders on August 12, 2024.
- The meeting is scheduled for 11:00 a.m. Israel time at Goldfarb Gross Seligman & Co. in Tel Aviv.
- This filing updates the Proxy Statement previously filed on July 8, 2024.
- No financial performance data is included in this specific report.